AU2003247505A1 - Spliceosome mediated rna trans-splicing in stem cells - Google Patents

Spliceosome mediated rna trans-splicing in stem cells Download PDF

Info

Publication number
AU2003247505A1
AU2003247505A1 AU2003247505A AU2003247505A AU2003247505A1 AU 2003247505 A1 AU2003247505 A1 AU 2003247505A1 AU 2003247505 A AU2003247505 A AU 2003247505A AU 2003247505 A AU2003247505 A AU 2003247505A AU 2003247505 A1 AU2003247505 A1 AU 2003247505A1
Authority
AU
Australia
Prior art keywords
stem cell
nucleic acid
acid molecule
mrna
target binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003247505A
Other languages
English (en)
Inventor
John Englehardt
Xiao Ming Liu
Lloyd G. Mitchell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Iowa Research Foundation UIRF
VirxSys Corp
Original Assignee
University of Iowa Research Foundation UIRF
VirxSys Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Iowa Research Foundation UIRF, VirxSys Corp filed Critical University of Iowa Research Foundation UIRF
Publication of AU2003247505A1 publication Critical patent/AU2003247505A1/en
Assigned to INTRONN, INC., UNIVERSITY OF IOWA RESEARCH FOUNDATION reassignment INTRONN, INC. Amend patent request/document other than specification (104) Assignors: Refer to Publication History
Assigned to VIRXSYS CORPORATION, UNIVERSITY OF IOWA RESEARCH FOUNDATION reassignment VIRXSYS CORPORATION Request for Assignment Assignors: INTRONN, INC.
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0688—Cells from the lungs or the respiratory tract
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2003247505A 2002-06-05 2003-06-05 Spliceosome mediated rna trans-splicing in stem cells Abandoned AU2003247505A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38659402P 2002-06-05 2002-06-05
US60/386,594 2002-06-05
PCT/US2003/017954 WO2003104416A2 (en) 2002-06-05 2003-06-05 Spliceosome mediated rna trans-splicing in stem cells

Publications (1)

Publication Number Publication Date
AU2003247505A1 true AU2003247505A1 (en) 2003-12-22

Family

ID=29736184

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003247505A Abandoned AU2003247505A1 (en) 2002-06-05 2003-06-05 Spliceosome mediated rna trans-splicing in stem cells

Country Status (6)

Country Link
US (1) US20040180429A1 (https=)
EP (1) EP1549755A4 (https=)
JP (1) JP2005528912A (https=)
AU (1) AU2003247505A1 (https=)
CA (1) CA2488249A1 (https=)
WO (1) WO2003104416A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007518423A (ja) * 2004-01-23 2007-07-12 イントロン、インコーポレイテッド スプライセオソーム仲介型ｒｎａトランススプライシングを使用するアポａ−１及びその変異体の発現
EP2151248A1 (en) * 2008-07-30 2010-02-10 Johann Bauer Improved pre-mRNA trans-splicing molecule (RTM) molecules and their uses
EP3377116A4 (en) 2015-11-19 2019-07-10 The Trustees of The University of Pennsylvania COMPOSITIONS AND METHODS FOR CORRECTING ECG-RELATED EYE DISEASE
CA3097004A1 (en) 2018-04-17 2019-10-24 The Trustees Of The University Of Pennsylvania Trans-splicing molecules
JP2023535381A (ja) * 2020-07-17 2023-08-17 グリーンライト バイオサイエンシーズ インコーポレーテッド 遺伝子疾患の核酸治療薬
AU2023208612A1 (en) * 2022-01-18 2024-08-08 National University Of Singapore TRANS-SPLICING RNA (tsRNA)
AU2023269865A1 (en) 2022-05-13 2024-11-21 Ascidian Therapeutics, Inc. Abca4 trans-splicing molecules

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ241311A (en) * 1991-01-17 1995-03-28 Gen Hospital Corp Rna sequence having trans-splicing activity, plant strains
US6280978B1 (en) * 1995-12-15 2001-08-28 Intronn Holdings, Llc Methods and compositions for use in spliceosome mediated RNA trans-splicing
US6083702A (en) * 1995-12-15 2000-07-04 Intronn Holdings Llc Methods and compositions for use in spliceosome mediated RNA trans-splicing
DE69636937T3 (de) * 1995-12-15 2011-01-05 Virxsys Corp. Durch trans-spaltung erhaltene therapeutische molekule
CA2278734A1 (en) * 1997-01-23 1998-07-30 Immusol Incorporated Gene functional analysis and discovery using randomized or target-specific ribozyme gene vector libraries

Also Published As

Publication number Publication date
EP1549755A4 (en) 2006-09-20
US20040180429A1 (en) 2004-09-16
EP1549755A2 (en) 2005-07-06
WO2003104416A2 (en) 2003-12-18
JP2005528912A (ja) 2005-09-29
WO2003104416A3 (en) 2004-07-01
CA2488249A1 (en) 2003-12-18

Similar Documents

Publication Publication Date Title
DE69535560T2 (de) Ein verstärkter, durch viren vermittelter dna-transfer
JP3343357B2 (ja) レトロウイルスによる標的細胞への遺伝子導入方法
US6670177B2 (en) Methods for enhanced virus-mediated DNA transfer using molecules with virus-and cell-binding domains
EP0667791A4 (en) ISOLATION, GROWTH, DIFFERENTIATION AND GENE TECHNOLOGICAL MANIPULATION OF HUMAN MUSCLE CELLS.
Song et al. Functional cystic fibrosis transmembrane conductance regulator expression in cystic fibrosis airway epithelial cells by AAV6. 2-mediated segmental trans-splicing
WO2022120094A2 (en) Compositions and methods for the targeting of bcl11a
EP0457856A1 (en) Isolation growth and differentiation of human muscle cells
JPWO2001023545A1 (ja) 変異型ｆｒｔ配列を含有してなるｄｎａ
US20040180429A1 (en) Spliceosome mediated RNA trans-splicing in stem cells
US6033907A (en) Enhanced virus-mediated DNA transfer
CN109072220A (zh) 由成纤维细胞直接制造心脏祖细胞和心肌细胞的方法
US7759467B2 (en) Enhanced mediated DNA transfer
KR20230125806A (ko) 선천성 근이영양증의 치료를 위한 치료용 lama2 페이로드
DiGirolamo The potential of human bone marrow stromal cells as vehicles for ex vivo gene therapy applications
Zhang et al. Mesenchymal stem cells
Scarpa et al. Advances toward gene therapy
Spampinato et al. Transfer and expression of DNA constructs into cells by using retrovirus vectors: A new tool for pharmacological research
HK1107581A (en) Enhanced virus-mediated dna transfer
MXPA96004240A (en) Improved transfer of dna mediated by vi
JPWO1996028560A1 (ja) 新規細胞株

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: ADD THE NAME OF THE COAPPLICANT UNIVERSITY OF IOWA RESEARCH FOUNDATION

PC1 Assignment before grant (sect. 113)

Owner name: UNIVERSITY OF IOWA RESEARCH FOUNDATION; VIRXSYS CO

Free format text: FORMER APPLICANT(S): INTRONN, INC.

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application